OPKO Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on April 3, 2018. The report discloses a corporate governance event regarding the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Robert S. Fishel, M.D., as a new director, effective April 3, 2018. The Board determined that Dr. Fishel is independent under applicable SEC and Nasdaq rules. No related person transactions exist between Dr. Fishel and the Company.
Compensation and Governance Details
- Stock Options: Dr. Fishel received a grant of 40,000 stock options under the Company's 2016 Equity Incentive Plan.
- Exercise Price: The options have an exercise price of $3.04, based on the closing stock price on April 3, 2018.
- Additional Compensation: Dr. Fishel will receive standard compensation for non-employee directors and has entered into a standard director indemnification agreement.
- Background: Dr. Fishel is the CEO and President of Florida Electrophysiology Associates and holds leadership roles at Renaissance Properties, Catalyst Development Partners, ALSAR Ltd Partnership, and NewPace Medical.
Investor Verification Checklist
- Verify the independence status of Dr. Fishel against current Nasdaq listing standards.
- Review the terms of the 2016 Equity Incentive Plan regarding the 40,000 option grant.
- Confirm the absence of undisclosed related party transactions involving Dr. Fishel's other business affiliations.
- Check subsequent filings for any changes to the Board composition or compensation structure.